SYDNEY, Australia, Dec. 15 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis today announced that it had contracted Romedic B.V. to market and distribute its asthma diagnostic and management tool, Aridol, in the Netherlands. The appointment precedes the registration of Aridol by the mutual recognition procedure in the European Community where the Netherlands is part of the first wave of countries expected in March 2007.
Dr Alan Robertson, Pharmaxis CEO said "The European market remains a high priority for Pharmaxis and the Netherlands is a key market where despite its relatively small population, challenge tests like Aridol are already well established and used in significant volumes. Romedic is uniquely positioned to successfully introduce Aridol given its commanding position in the respiratory device market and its recent entry into the respiratory pharmaceuticals market."
Paul Roberts, Romedic Managing Director said "Aridol is a significant advance in asthma diagnosis and management. Subject to EU MRP approval it will be the first registered test in the Netherlands and we hope to both take share of the existing market and grow the total market size as physicians take advantage of the new capabilities offered by Aridol. By staying focused and dedicated to both the respiratory professionals and patients, Romedic has been able to build up an excellent reputation. Adding new, unique and highly innovative products like Aridol to our product portfolio we are able to meet customer expectations of being No 1 in the respiratory field.''
The total population affected by asthma in the Netherlands is estimated to be approximately 1.2 million.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au .
For more information about Aridol and Romedic, see http://www.pharmaxis.com.au/products/aridol/aridol_home.cfm and http://www.pharmaxis.com.au/library/2006_12_14_Romedic_NL.pdf .
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.
CONTACT: Alan Robertson -- Pharmaxis Chief Executive Officer Tel: +61-2-9454-7202 Fax: +61-2-9451-3622 Website: www.pharmaxis.com.au Released through: United States: Brandon Lewis, Trout Group Tel: +1-212-477-9007 Email: blewis@troutgroup.com Australia: Virginia Nicholls Tel: +61-417-610-824 Email: virginia.nicholls@pharmaxis.com.au
Pharmaxis LtdCONTACT: Alan Robertson of Pharmaxis, +61-2-9454-7202, or fax+61-2-9451-3622, arobertson@pharmaxis.com.au; Brandon Lewis in US of TroutGroup for Pharmaxis, +1-212-477-9007, blewis@troutgroup.com; VirginiaNicholls in Australia for Pharmaxis, +61-417-610-824
Web site: http://www.pharmaxis.com.au/
